Effectiveness of Text Message Reminders on Adherence to Inhaled Therapy in Patients With Asthma : Prospective Multicenter Randomized Clinical Trial by Almonacid, Carlos et al.
Original Paper
Effectiveness of Text Message Reminders on Adherence to
Inhaled Therapy in Patients With Asthma: Prospective Multicenter
Randomized Clinical Trial
Carlos Almonacid1, MD, PhD; Carlos Melero2, MD, PhD; Antolín López Viña3, MD, PhD; Carolina Cisneros4, MD,
PhD; Luis Pérez de Llano5, MD, PhD; Vicente Plaza6, MD, PhD; Juan Luis García-Rivero7, MD, PhD; Auxiliadora
Romero Falcón8, MD, PhD; Jacinto Ramos9, MD, PhD; Teresa Bazús González10, MD, PhD; María Andrés Prado11,
MD, PhD; Alfonso Muriel12, MD, PhD
1Department of Respiratory Medicine, Instituto Ramón y Cajal de Investigación Sanitaria, University of Alcala de Henares, Madrid, Spain
2Department of Respiratory Medicine, Hospital Universitario 12 de Octubre, Institute for Health Research (i+12), Complutense University of Madrid,
Madrid, Spain
3Department of Respiratory Medicine, Hospital Universitario Puerta de Hierro, Autonoma University of Madrid, Majadahonda, Spain
4Department of Respiratory Medicine, Hospital Universitario La Princesa, Autónoma University of Madrid, Madrid, Spain
5Department of Respiratory Medicine, Hospital Universitario Lucus Augusti, University of Lugo, Lugo, Spain
6Department of Respiratory Medicine, Hospital de la Santa Creu i Sant Pau, Institut d’Investigació Biomédica Sant Pau, Autònoma University of
Barcelona, Barcelona, Spain
7Department of Respiratory Medicine, Laredo Hospital, Laredo, Spain
8Department of Respiratory Medicine, Hospital Universitario Reina Sofia, University of Cordoba, Córdoba, Spain
9Department of Respiratory Medicine, Hospital Universitario de Salamanca, University of Salamanca, Salamanca, Spain
10Department of Respiratory Medicine, Hospital Universitario Central de Asturias, University of Oviedo, Oviedo, Spain
11Department of Health Information Management, Fundación Jimenez Diaz, Madrid, Spain
12Unit of Clinical Biostatistics, Instituto Ramón y Cajal de Investigación Sanitaria, Consorcio Centro de Investigación Biomédica en Red de Epidemiología
y Salud Pública, University of Alcala de Henares, Madrid, Spain
Corresponding Author:
Carlos Almonacid, MD, PhD
Department of Respiratory Medicine
Instituto Ramón y Cajal de Investigación Sanitaria
University of Alcala de Henares
Ctra. De Colmenar Viejo, km. 9,100
Madrid,
Spain
Phone: 34 655 534 475
Email: caralmsan@gmail.com
Abstract
Background: Poor adherence to inhaled medication in asthma patients is of great concern. It is one of the main reasons for
inadequate asthma control.
Objective: The goal of the research was to determine if motivational messages using short message service (SMS, or text)
improved adherence to inhaled medication in patients with asthma.
Methods: A prospective multicenter randomized parallel-group clinical trial was conducted in 10 asthma clinics in Spain.
Adherence was assessed with electronic monitors (Smartinhaler, Adherium Ltd) connected to inhalers. Patients in the SMS group
received psychologist-developed motivational messages every 3 days for 6 months.
Results: There were 53 patients in the SMS group and 88 patients in the control group. After 6 months, mean electronic adherence
was 70% (SD 17%) in the intervention group and 69% (SD 17%) in the control group (P=.82). Significant differences between
the study groups in morning and evening adherence to inhaled therapy, asthma control, exhaled nitric oxide levels, or improvement
of lung functions were not observed.
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Conclusions: Motivational messages were not useful to improve adherence to inhaled asthma medication compared with usual
care.
(JMIR Form Res 2021;5(2):e12218) doi: 10.2196/12218
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Introduction
Epidemiological studies show a high prevalence of poor asthma
control [1-3]. Poor adherence is one of the most frequent causes
of this problem [2-18]. The measurement of adherence to
inhalers is a complicated task. Different methods have been
used in daily practice, including clinical judgment, response to
treatment, generally validated self-report questionnaires [19],
or specifically designed instruments such as the Test of
Adherence to Inhalers [20,21]. All these methods tend to
overestimate treatment adherence [22,23]. Exhaled nitric oxide
(FeNO) measurement has been proposed as an objective
technique to measure treatment compliance [24]. In the last 30
years, electronic monitoring devices have been developed with
this proposal [25-28]. These devices can record the time and
number of doses taken and remind the patient to take medication.
Adherence to inhaled therapy depends on multiple factors.
Asthma education programs plus information and
communication technologies could be more useful to improve
adherence than using them separately. All cell phones can send
or receive short message service (SMS, or text) messages, which
are a convenient, widely used mode of communication [29-32].
It has been shown that text messages improve appointment
adherence [10], but very little research has focused on the effect
of messages to reinforce adherence using SMS.
Several studies reviewed the effect of reminders on asthma
control and adherence to treatment [33-40]. Only a few studies
have used electronic devices to assess adherence to inhalers. In
these studies, reminders were also sent through the same
electronic device (SmartTrack or Smartinhaler [both Adherium
Ltd]) that measured adherence to treatment, not through SMS
[39,40]. Other studies used self-report questionnaires to measure
inhaler adherence, but this leads to decreases the quality of the
results. To date, a benefit in adherence to treatment from
motivational text messages sent to a cell phone has not been
reported.
The objective of this study is to measure the effect of
motivational messages designed by a psychologist on treatment




We conducted a parallel-group randomized controlled trial in
patients with moderate or severe asthma at 10 university
hospitals in Spain. Patients were recruited from 2013 to 2014.
Patients were randomized to an SMS group or a control group;
follow-up was for 6 months.
Participants
The eligibility criteria for participants were (1) aged 18 to 85
years, (2) asthma diagnosed according to the Global Initiative
for Asthma (GINA) criteria [41], (3) all patients treated with
maintenance therapy according GINA guidelines, (4) currently
own cell phone, (5) not currently being treated with systemic
corticosteroids or biologic drugs, (6) not currently participating
in another research study.
Exclusion criteria were (1) inability to use inhaler devices [30];
(2) other associated chronic respiratory disease (eg, chronic
obstructive pulmonary disease); (3) previous participation in a
study using SMS-related asthma reminders (4) asthma
exacerbation within 3 months of inclusion in the study (defined
by oral corticosteroid use, emergency department visit, or
hospitalization); (5) previous treatment with
budesonide/formoterol as maintenance and reliever therapy; (6)
other uncontrolled severe medical conditions.
Interventions
The SMS group received psychologist-developed motivational
messages every 3 days for 6 months in addition to usual care
recommendations according to GINA guidelines [41]. SMS
messages were not reminders to take a dose of medication. The
control group was treated with general care recommendations
alone according to GINA guidelines [41]. Four study visits were
required (1 for enrollment and 3 for follow-up) in both groups.
Outcome data were collected at the clinic by study staff in V0,
V1 (1 month later), V3 (3 months later), and V6 (6 months
later—end of study).
Medications and Inhaler Monitoring
All patients received a SmartTrack device (Smartinhaler
[Adherium Ltd]; Figure 1) that clipped on their ICS/LABA
inhaler. SmartTrack is an electronic device that allows
measuring adherence to the inhalers. Each puff is recorded in
the device memory. SmartTrack records the date and time the
inhaler was used and the number of puffs taken. SmartTrack
features include reminders, onscreen questions about asthma
control, and medication feedback viewing online, but these have
been deactivated. After the device was activated during the
enrollment (visit 0), it recorded the date and time of all
maneuvers to measure adherence to treatment. The data were
uploaded to a secure cloud server with local backup to the
investigator’s computer.
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Figure 1. SmartTrack devices connected to pressurized metered-dose inhaler (left) and Turbuhaler inhalation device (right).
Patients were treated with an ICS/LABA inhaler for maintenance
therapy (fluticasone propionate/salmeterol Accuhaler/Diskus
inhaler, budesonide/formoterol Turbuhaler inhaler, or
beclomethasone/formoterol metered-dose inhaler). They also
used albuterol pressurized metered-dose inhaler as rescue
medication. Device reliability and precision have been reported
according to other publications [38].
SmartTrack Training and Monitoring
Electronic monitoring via the Smartinhaler was used to assess
adherence to inhaled asthma therapy. All patients received brief
instructions on the use of the SmartTrack. Patients with
adherence higher than 80% were considered regular adherents.
Electronic monitors were attached to participant controller
medications in the SMS and control groups.
Text Messages
Patients assigned to the intervention group only received SMS
communications about the importance of asthma medication
every 3 days for 6 months; messages were not reminders to take
a dose of medication. The messages, written by a psychologist
in collaboration with pulmonologists, were randomly switched
every 3 days and include the following:
• Remember that performing the treatment of inhaled
medication keeps your asthma controlled.
• Inhaled medication helps to maintain asthma control.
• Remember to take inhaled medication; it keeps you well.
• Have you taken your inhaled medication?
• Do you take your inhaled medication in the morning and
the evening?
• Maybe now is the time to take your inhaled medication.
• Remember to take inhaled medication as prescribed by your
doctor.
Asthma Education
All patients were provided an asthma action plan on the first
day written in accordance with the GINA guidelines. Inhaler
technique was reviewed, and any problems were corrected. At
each visit, inhaler technique and the asthma action plan were
reviewed.
Asthma Control
Asthma control was measured using the Asthma Control Test
(ACT) [42], and a score ≥20 identified well-controlled asthma
patients.
Pulmonary Function
Spirometry with bronchodilator test was performed according
to the European Respiratory Society/American Thoracic Society
(ERS/ATS) guidelines [43]. Values for the Mediterranean
population were used [44]. Forced expiratory volume in 1
second (FEV1) pre and postbronchodilator were measured.
Fractional Exhaled Nitric Oxide
An FeNO level was measured before spirometry using the
equipment available in each center. The test was performed
following the ERS/ATS recommendations [45].
Outcomes
Demographic data, ACT, lung function (spirometry), FeNO
levels, and exacerbation history in the previous year were
collected at the enrollment visit (V0). ACT, lung function, FeNO
levels, and exacerbation history were also collected at V1, V3,
and V6.
The primary outcome was adherence to inhaled medication.
SmartTrack devices were used to quantify adherence to control
medication. The secondary outcomes were asthma control
measured by the ACT, spirometry parameters (FEV1, forced
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vital capacity, and FEV1/forced vital capacity ratio), FeNO
levels, number of asthma exacerbations, visits to the emergency
department, and hospital admissions due to asthma.
Sample Size
The sample size was calculated according to an adherence rate
to inhaled asthma therapy between 30% and 70% [9]. On the
assumption of the maximal uncertainty of 50% and considering
a clinically relevant difference of 25%, with a type I error of
.05, a power of 80%, and a 20% loss, 73 patients per arm were
needed (total 146 patients).
Randomization, Blinding, and Allocation Concealment
We generated the 2 comparison groups using simple
randomization with an equal allocation ratio by referring to a
table of random numbers. A mathematician, also in charge of
randomization of the SMS sending, generated the sequences of
random allocation, who enrolled participants, and who assigned
participants to interventions and SMS sending.
Blinding of patients was not possible. To avoid bias and with
ethics approval, physicians were not notified about the
SmartTrack recording function or SMS intervention until the
study ended.
Statistical Methods
Categorical variables were expressed as frequencies and
percentages and continuous variables as means and standard
deviations. The chi-square or Fisher exact test were used for
the analysis of categorical variables, and the Student t test or
Mann-Whitney U test were used for the comparison of
quantitative variables according to the standard or nonnormal
distribution of variables. Tests were 2-tailed. Statistical
significance was set at P<.05. Statistical analyses were
performed using the SPSS Statistics version 20.0 (IBM Corp).
Ethics Approval and Trial Registration
The clinical research ethics committees of the participating
centers approved the study. All participants provided written
informed consent. The study was classified by the Spanish
Agency of Medicines and Medical Devices as a
noninterventional imposed postauthorization safety study, and
for this reason we were not required to register the clinical trial.
Results
Patient Participants
Of patients recruited, 63.8% (97/152) were women. At the first
data collection time point, the mean age was 48.9 (SD 16.7)
years, and the mean duration of asthma was 16.5 (SD 13) years.
A total of 6.6% (10/152) of patients were current smokers. Most
patients were well controlled at enrollment, with a mean ACT
score of 20.2 (SD 4.5) points. The mean FEV1 before the
bronchodilation test was 79% (SD 17.9%) predicted, the mean
FEV1 after bronchodilation test was 82.5% (SD 16.2%)
predicted, and the mean FeNO level was 37.9 (SD 35.9) ppb.
A total of 13.2% (20/152) of patients reported one or more
exacerbations during the last 12 months, 15.8% (24/152)
reported an episode of asthma-related urgent health care
utilization and prednisone use in the previous year, and 5.9%
(9/152) required admission to hospital.
A failure with the randomization program unbalanced the
number of patients in both arms. During the study period, 57
patients were assigned to the intervention group, and 95 to the
control group. At follow-up, 11 patients were excluded because
of the total failure of the electronic monitoring device. The final
analysis included 53 patients in the intervention group and 88
in the control group. The flowchart of the study population is
shown in Figure 2. Demographic and baseline characteristics
were similar between groups, apart from a lower proportion of
men and university education in the SMS group (Table 1).
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Figure 2. Flow diagram of the progress through the phases of a parallel randomized trial of two groups.
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Table 1. Clinical characteristics of patients at baseline.
P valueControl group (n=95)SMSa group (n=57)Variable
.0540 (42)15 (26)Gender, male, n (%)
.4048 (16.9)50.4 (16.4)Age in years, mean (SD)
Education level, n (%)
.4061 (64)47 (82)Primary/secondary studies
.4020 (21)7 (12)University degree





Smoking history, n (%)
.756 (6)4 (7)Current smoker
.7534 (36)17 (30)Ex-smoker
.7555 (58)36 (63)Never smoker
.9116 (17)10 (18)Self-management education program, n (%)
Asthma history, mean (SD)
.9816.5 (14.3)16.6 (11.6)Years from diagnosis
.1013.2 (12.1)13.3 (10.3)Years from starting treatment
.786.8 (7.8)7.2 (7)Years from follow-up in outpatient clinics




Inhalation technique, correct steps, n (%)
.2275 (79)40 (70)Acceptable
.2220 (21)17 (30)Unacceptable
Asthma-related events in the previous 12 months, mean (SD)
.210.4 (0.8)0.6 (1.2)Exacerbations
.790.2 (0.7)0.2 (0.6)Emergency department visits
.760.04 (0.2)0.05 (0.2)Hospital admission
.6920.0 (4.8)20.3 (4.2)Asthma Control Test, mean (SD)
.1833.7 (34.3)42.2 (37.5)FeNOc level, ppb, mean (SD)
.9279.5 (18.4)79.0 (17.5)FEV1d before bronchodilation test, % predicted, mean (SD)
.1685.3 (15.7)79.6 (16.7)FEV1 after bronchodilation test, % predicted, mean (SD)
aSMS: short message service.
bpMDI: pressurized metered-dose inhaler.
cFeNO: exhaled nitric oxide.
dFEV1: forced expiratory volume in 1 second.
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Adherence data were recorded throughout the study starting
from enrollment, and 92.8% (141/152) of patients had
analyzable SmartTrack data. No adherence data were available
for 7.2% (11/152) of patients due to device failure; 21.7%
(33/152) of SmartTracks monitored adherence for at least 90
days, 11.2% (17/152) operated fine for between 90 and 179
days, and 59.9% (91/152) worked precisely until the study
ended.
The data transmission software that communicated with the
Smartinhaler platform failed throughout the study in most of
the participating centers since it did not work with the hospital
proxy servers. Due to this failure, the backup files generated
during each visit were used for the analysis. Differences between
the study groups were not found in SmartTrack failures (P=.51).
After 6 months, the mean electronic adherence was 70% (SD
17%) in the intervention group and 69% (SD 17%) in the control
group (P=.82). Adherence to inhalers was higher in both groups
in the morning (control group 79% [SD 19%] vs 60% [SD 24%]
in the afternoon and SMS group 80% [SD 23%] vs 59% [SD
29%] in the afternoon; Table 2).
Table 2. Results at the end of the study.
P valueControl group (n=88)SMSa group (n=53)Variables
.8269 (17)70 (17)Adherence %, mean (SD)
.4478 (19)80 (23)Morning adherence %, mean (SD)
.7560 (24)59 (29)Evening adherence %, mean (SD)
.4622.1 (3.5)21.6 (3.7)Asthma Control Test score, mean (SD)
.1428.3 (22.0)36.5 (35.5)FeNOb level, ppbc, mean (SD)
.4280.9 (18.0)77.3 (16.2)FEV1d before bronchodilation test, % predicted, mean (SD)
.7384.5 (16.2)85.9 (12.4)FEV1 after bronchodilation test, % predicted, mean (SD)








—00Hospital admission for asthma, n (%)
aSMS: short message service.
bFeNO: exhaled nitric oxide.
cppb: parts per billion.
dFEV1: forced expiratory volume in 1 second.
Secondary Outcomes
At the end of the study (V6), no differences were found between
the SMS and control group in ACT, FEV1, FeNO levels,




In this study, motivational SMS was not associated with an
improvement in adherence to inhaled medication. We also found
no significant differences in secondary variables, asthma control,
lung function, exhaled nitric oxide levels, or exacerbations due
to asthma.
Education strategies are useful to improve adherence to asthma
therapy [10]. Few studies have examined the effect of SMS
reminders on adherence to asthma treatment. Strandbygaard et
al [46] conducted a 12-week study with 26 asthma patients
randomized to the SMS group (n=12) or control group (n=14).
The SMS group received this message daily: “Remember to
take your asthma medication morning and evening. From the
Respiratory Unit.” A medicine dose-count for Diskus inhaler
was used to assess adherence. The mean adherence rate
increased in the SMS group and decreased in controls, with a
difference in mean adherence rate between the 2 groups after
12 weeks of 17.8% (95% CI 3.2%-32.3%; P=.02). Changes in
adherence in the SMS group, however, were not associated with
clinical or functional improvement. Few patients were included
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in this study, and adherence may have been overestimated due
to the possibility to take actions before the medical visit.
In another study, Charles et al [47] used the audiovisual
reminder function on the Smartinhaler metered-dose inhaler
device. After 12 weeks, the absolute difference in the median
percentage of medication taken between the intervention (n=55)
and control (n=55) groups was 18% (95% CI 10%-26%;
P<.001). But, again, no improvements in clinical or lung
functions were observed.
In a 6-month cluster-randomized study, Foster et al [35] assessed
the effect of inhaler reminders plus adherence feedback (n=21)
versus usual care or personalized discussion with the general
practitioners (n=22) in the primary care setting. Reminders were
associated with improvements in adherence (73% [SD 26%] vs
46% [SD 28%] of prescribed daily doses, P<.001) as well as
with an improvement in the ACT but without differences
between the study groups.
In a recent systematic review of interventions aimed at
improving adherence to inhaled corticosteroids for asthma, 11
studies assessing electronic trackers or reminders versus control
were analyzed [10]. Electronic trackers or reminders led to better
adherence of 19 percentage points (95% CI 14.47-25.26; 6
studies; moderate-quality evidence), but a clear benefit on
clinical outcomes was not found.
Limitations
In our study, a simple intervention based on motivational SMS
sent every 3 days for 6 months was not adequate to improve
adherence. Different reasons may account for this adverse
finding. First, the messages sent were motivational; they were
not reminders for taking medication. Second, the pattern of
nonadherence behavior (eg, erratic, deliberate, unwitting) [21]
was not evaluated nor were patients stratified according to a
nonadherent model. Third, asthma was well controlled at
baseline as shown by high ACT scores and lung function
parameters; the magnitude of improvement depends to a large
extent on the degree of control of the disease before the
intervention.
An interesting finding of this study, in which all patients had
twice-daily medication schedules, is that adherence rates were
higher in the morning than in the evening. It is possible that in
patients on single-dose inhaled medication regimens, SMS could
have had a more significant impact on adherence.
Although the Smartinhaler is accurate in recording and retaining
actuation data [48,49], potential malfunction during real-life
use by patients is possible. In our study, failure of
communication technology occurred in all centers without
differences between the study groups; in these cases, however,
analyses were performed using backup files. Only 91% (SD
59.9%) of the Smartinhalers worked fine and collected
information until the study ended.
In our study, patients were recruited in specialized asthma units
established in different hospitals throughout Spain for the
management of patients with severe and difficult-to-control
asthma [50]. Therefore, it is possible that this particular
circumstance may account for the adequate adherence at baseline
and proper control of asthma before enrollment and at the end
of the study.
Conclusions
In summary, in this prospective randomized clinical study,
reinforcement of adherence to inhaled asthma medication using
motivational SMS via cell phones was not capable of improving
adherence. Mobile health interventions are increasingly popular
for implementing on a large scale in different chronic health
conditions [51-53], but further research into these issues is
needed. Despite the negative results that may be justified
because of the study’s limitations as described above, the study’s
results are not conclusive. However, an interesting fact that can
be seen in both groups is that morning adherence to the inhaler
is much higher than afternoon adherence. These data should be
verified in a new well-designed clinical trial that could reinforce
the use of ultralong action treatments, which only need to be
taken once a day, in order to improve the adherence and control
of asthma.
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